Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

14.46USD
3:59pm EST
Change (% chg)

$0.79 (+5.78%)
Prev Close
$13.67
Open
$13.64
Day's High
$14.73
Day's Low
$13.64
Volume
81,715
Avg. Vol
102,104
52-wk High
$31.69
52-wk Low
$11.45

Latest Key Developments (Source: Significant Developments)

Apellis Pharmaceuticals QTRLY Loss Per Share $0.64
Tuesday, 13 Nov 2018 08:00am EST 

Nov 13 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.CASH POSITION OF $220.6 MILLION AT QUARTER-END.QTRLY LOSS PER SHARE $0.64.COMMENCED PHASE 3 PROGRAM OF APL-2 IN GEOGRAPHIC ATROPHY.Q3 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.  Full Article

Apellis Pharmaceuticals Qtrly Loss Per Share $0.43
Monday, 30 Apr 2018 04:00pm EDT 

April 30 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.43.APELLIS PHARMACEUTICALS - APL-2 IN GEOGRAPHIC ATROPHY AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ON TRACK TO ADVANCE INTO PHASE 3 TRIALS IN 2H18.  Full Article

Apellis Pharmaceuticals Files For Offering Of 5 Million Shares Of Common Stock
Monday, 16 Apr 2018 05:00pm EDT 

April 16 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS INC FILES FOR OFFERING OF 5,000,000 SHARES OF COMMON STOCK - SEC FILING.  Full Article

Apellis Pharmaceuticals Q4 Loss Per Share $0.61
Monday, 19 Mar 2018 04:30pm EDT 

March 19 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.61.  Full Article

Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment
Wednesday, 20 Dec 2017 05:30pm EST 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM EVALUATING APL-2 PLANNED TO BEGIN IN SECOND HALF OF 2018.APELLIS PHARMACEUTICALS - PHASE 3 PROGRAM TO CONSIST OF TWO IDENTICAL 600-PATIENT STUDIES TO ASSESS EFFICACY,SAFETY.APELLIS PHARMACEUTICALS INC - PHASE 3 TRIALS EVALUATING APL-2 WILL BE SUBSTANTIALLY SIMILAR IN DESIGN TO APELLIS' ONGOING PHASE 2 FILLY TRIAL.  Full Article

Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc
Tuesday, 21 Nov 2017 04:58pm EST 

Nov 21 (Reuters) - Apellis Pharmaceuticals Inc :Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing.  Full Article

Apellis Pharmaceuticals announces closing of its IPO
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Apellis Pharmaceuticals Inc ::Apellis pharmaceuticals announces closing of its initial public offering.  Full Article

Apellis Pharma shares debut about 3.6 pct above IPO price
Thursday, 9 Nov 2017 10:13am EST 

Nov 9 (Reuters) - :Apellis Pharmaceuticals Inc shares open at $14.50 in debut on the NASDAQ versus IPO price of $14 per share‍​.  Full Article

Apellis prices IPO of 10.7 mln common shares at $14/shr
Wednesday, 8 Nov 2017 09:38pm EST 

Nov 9 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals announces pricing of initial public offering.Says initial public offering of 10.7 million common shares priced at $14.00 per share.  Full Article

Apellis Pharmaceuticals sees IPO of 10.71 mln shares‍​ of common stock
Monday, 30 Oct 2017 10:50am EDT 

Oct 30 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals Inc sees IPO of 10.71 million shares‍​ of common stock to be priced between $13.00 and $15.00 per share - sec filing.  Full Article